In this episode of Diasorin’s Beyond the Result podcast, host Angelo Rago speaks with Margie Morgan, PhD, director of Clinical Microbiology at Cedars-Sinai Medical Center in Los Angeles.Highlights include: - Developing testing strategies that manage costs and improve patient outcomes, all while understanding that there is no “one-size-fits-all” approach that will work for everyone. At Cedars-Sinai, a large academic medical center, the patient population is large and quite diverse, adding complexity to their testing strategies.- Collaboration is essential for clinical labs. For microbiology, it makes sense to team up with colleagues from infection control, infectious disease, and pharmacy. “Don’t try to do it by yourself,” Dr. Morgan advises.- The evolution of molecular testing means that the “more is better” approach favored by labs a decade ago is no longer practical or recommended. Today, targeted testing with the ability to reflex to a larger multiplex panel is a better approach for many clinical situations, and it helps manage costs so patients don’t go home to exorbitant testing bills.- To help physicians select the most appropriate test, Dr. Morgan’s team has gotten creative. They use soft stops and hard stops built into the test ordering software, and have even rearranged the order in which tests are presented on the screen to provide a gentle nudge toward targeted tests to help with diagnostic stewardship.Credits: Host – Angelo Rago, President of Luminex division of Diasorin Guest – Margie Morgan, PhD, director of Clinical Microbiology at Cedars-Sinai in Los AngelesProducers – Stephanie Ibbotson, Sr. Director of Strategic Marketing and Market Access and Michelle Tabb, PhD, Chief Scientific Officer Editor – Britta Good, Graphic Designer, Global Marketing Sign up to be notified for new episodes: https://us.diasorin.com/en/molecular-diagnostics?utm_source=YouTube&utm_medium=YT-description&utm_campaign=Podcast&utm_id=Corporate&utm_term=Ep4
This episode of Diasorin’s Beyond the Result podcast features host Angelo Rago chatting with Mark Zaydman, MD, PhD, assistant professor of pathology and immunology in the Division of Laboratory and Genomic Medicine of Washington University in St. Louis.Highlights include: • The transition to value-based medicine will not be feasible without clearly defining value and determining how to measure it. Until then, the focus on value is often misinterpreted as cost-cutting without a clear patient benefit.• Establishing value in laboratory medicine requires a clear understanding of how a clinician will use test results — will they lead to a material change in patient care and, ultimately, patient outcomes? Or could those test results have been easily predicted from other clinical data points, in which case they offer little new value?• With so many stakeholders across healthcare and complex relationships among them, the best way to get alignment is by putting patients at the center and focusing on better outcomes as the primary goal.• Collaborations across stakeholders, including industry partners, will be essential for creating more personalized care for patients.Credits: Host – Angelo Rago, President of Luminex division of Diasorin Guest – Mark Zaydman, MD, PhD, assistant professor of pathology and immunology in the Division of Laboratory and Genomic Medicine of Washington University in St. LouisProducers – Stephanie Ibbotson, Sr. Director of Strategic Marketing and Market Access and Michelle Tabb, PhD, Chief Scientific Officer Editor – Britta Good, Graphic Designer, Global Marketing Sign up to be notified for new episodes:
In this episode of the Beyond the Result podcast, Diasorin’s Angelo Rago chats with Nathan Ledeboer, medical director of clinical microbiology and molecular diagnostics at the Medical College of Wisconsin.
Highlights include:
- The shift from a painstakingly slow retrospective analysis to a faster, prospective approach has allowed the clinical laboratory team to advance its diagnostic stewardship efforts and improve testing efficiency in many clinical departments.
- The main difference came from getting buy-in from the system’s executive team, which was looking for cost savings and increased efficiencies after the pandemic. Support from leadership provided access to more resources, such as an analyst who could mine more information from electronic medical records.
- Securing early wins allowed the clinical lab team to generate more excitement about diagnostic stewardship and its potential to improve outcomes while reducing costs. Now, clinicians from a number of departments are working closely with the laboratory to develop decision support tools that will make it easier to order appropriate testing for each situation.
Credits:
Host – Angelo Rago, President of Luminex division of Diasorin
Guest – Nathan Ledeboer, medical director of clinical microbiology and molecular diagnostics at the Medical College of Wisconsin
Producers – Stephanie Ibbotson, Sr. Director of Strategic Marketing and Market Access and Michelle Tabb, PhD, Chief Scientific Officer
Editor – Britta Good, Graphic Designer, Global Marketing
Sign up to be notified for new episodes: https://info.diasorin.com/beyond-the-result-sign-up
https://us.diasorin.com/en/molecular-diagnostics?utm_source=YouTube&utm_medium=YT-description&utm_campaign=Podcast&utm_id=Corporate&utm_term=Ep2
Welcome to the inaugural episode of Beyond the Result: Customizing Infectious Disease Diagnostics for Better Care podcast where we go deeper than the test result! Hosted by Angelo Rago at Diasorin, this podcast will feature laboratory experts with helpful perspectives on the value of diagnostic stewardship programs.
In this episode, Angelo interviews James Snyder, a professor in the Department of Pathology and Laboratory Medicine and Chief of Microbiology at the University of Louisville Hospital.
They dive into diagnostic stewardship, breakdown how syndromic testing has affected diagnostic stewardship, and discuss how your lab can join the diagnostic stewardship revolution.
Resources:
1. Olver P, Bohn MK and Adeli K. "Central role of laboratory medicine in public health and patient care" Clinical Chemistry and Laboratory Medicine (CCLM) 61, no. 4 (2023): 666-673. https://doi.org/10.1515/cclm-2022-1075
2. CLSI. Developing and Managing a Medical Laboratory (Test) Utilization Management Program. 1st ed. CLSI report GP49. Wayne PA: Clinical and Laboratory Standards Institute; 2017.
3. Gonzalez K and Amicarelli G. “Diagnostic Stewardship for Multiplex Respiratory Testing: Flexibility Is the Name of the Game.” White Paper. Diasorin. WP746579.0624.
4. Ibbotson S and Parsons B. “For Respiratory Testing, a Flexible Model Helps Laboratories Address the Reimbursement Responsibility,” White Paper. Diasorin. WP765450.US.0724
5. Singh HK., Claeys KC, Advani SD, Ballam YJ, et al. “Diagnostic Stewardship to Improve Patient Outcomes and Healthcare-Associated Infection (HAI) Metrics.” Infection Control & Hospital Epidemiology 45, no. 4 (2024): 405–11. https://doi.org/10.1017/ice.2023.284
6. Eastwood B. “How Do Data Silos Impede Patient Care and Provider Efficiency?” Health Tech Magazine. Published April 22, 2025. Web. https://healthtechmagazine.net/article/2025/04/how-do-data-silos-impede-patient-care-and-provider-efficiency
Credits:
Host – Angelo Rago, President of Luminex division of Diasorin
Guest – James Snyder, Chief of Microbiology at the University of Louisville Hospital
Producers – Stephanie Ibbotson, Sr. Director of Strategic Marketing and Market Access and Michelle Tabb, PhD, Chief Scientific Officer
Editor – Britta Good, Graphic Designer, Global Marketing
Sign up to be notified for new episodes: https://info.diasorin.com/beyond-the-result-sign-up
